MTD
Mettler-Toledo International Inc.1386.45
-26.02-1.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
28.56BP/E (TTM)
34.60Basic EPS (TTM)
40.07Dividend Yield
0%Recent Filings
8-K
8-K
Exec transition amendment signed
Mettler-Toledo amended Marc de La Guéronnière's employment agreement on October 21, 2025, setting up 2026 as a transition year toward his potential retirement at year-end. He'll work at 50% commitment, with base salary cut to EUR 140,000 annually—half his prior rate—while eligible for pro-rata bonuses and a EUR 150,000 transition incentive payable in 2027 if duties hand off smoothly. No new equity grants, but prior awards vest normally. This eases leadership handover without abrupt gaps.
8-K
Perversi joins MTD board
Mettler-Toledo International Inc. appointed Pablo Perversi to its board of directors, effective November 6, 2025, expanding the board from eight to nine members. Perversi, President of Europe at Danone and a veteran of over 30 years in food industry leadership at Unilever and Barry Callebaut, brings expertise in a key market for the company's precision instruments. His independent status aligns with NYSE standards. This addition bolsters strategic insights into global food operations.
8-K
Q2 sales up 2% local currency
Mettler-Toledo reported Q2 2025 sales of $983.2 million, up 4% in USD but 2% in local currency amid tough markets. Adjusted EPS climbed 5% to $10.09, buoyed by innovation and strategic wins, while adjusted operating profit held flat at $283.3 million. Tariffs sting with $60 million annualized costs, yet mitigation keeps full-year adjusted EPS outlook at $42.10-$42.60, up 2-4%. Headwinds persist from shipping delays and trade woes.
10-Q
Q2 FY2025 results
Mettler-Toledo posted solid Q2 revenue of $983M, up 4% y/y yet flat YTD at $1.87B amid tariff headwinds and prior shipping recovery. Gross margins dipped to 59.0% from 59.7%, hit by higher import costs but buoyed by pricing and SternDrive efficiencies; operating income held steady at $248.7M pre-tax, down slightly y/y while EPS fell to $9.76 from $10.37 on share buybacks. Service revenue climbed 6% y/y, fueling lab (56% of sales) and industrial (39%) segments, with China flat but Other regions surging 12%. Cash flow from operations reached $431M YTD, supporting $438M in repurchases; total debt stands at $2.18B with $493M revolver availability and $62M cash. New 3.8% Euro notes closed in January 2025 for €100M, refinancing debt through 2035. Tariffs pose the sharpest risk, potentially eroding margins further.
A
Agilent Technologies, Inc.
139.19-1.41
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
ILMN
Illumina, Inc.
131.56-3.36
MLAB
Mesa Laboratories, Inc.
78.63+0.80
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89